ArticleThe Journal of experimental medicine2019
c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.
Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Mapping the functional dark proteome in cancer.Nature reviews. Cancer · 2026Review
- TEDD: a comprehensive database for translation efficiency dynamics.Nucleic acids research · 2026Article
- TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression.Oncogene · 2025Article
- G9a controls plasma cell differentiation through FOXO1 and ETS1 binding site regulatory networks.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- PRPS activity tunes redox homeostasis in Myc-driven lymphoma.Redox biology · 2025Article
- Functional screen identifies RBM42 as a mediator of oncogenic mRNA translation specificity.Nature cell biology · 2025Article
- Microproteins in cancer: identification, biological functions, and clinical implications.Trends in genetics : TIG · 2025Review
- Upstream open reading frames: new players in the landscape of cancer gene regulation.NAR cancer · 2024Review
- Intra-promoter switch of transcription initiation sites in proliferation signaling-dependent RNA metabolism.Nature structural & molecular biology · 2023Article
- A dual role of RBM42 in modulating splicing and translation of CDKN1A/p21 during DNA damage response.Nature communications · 2023Article
- SRC2 controls CD4Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Proteomics Analysis of R-Ras Deficiency in Oxygen Induced Retinopathy.International journal of molecular sciences · 2023Article
- Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy.Haematologica · 2023Article
- Lessons in aging from Myc knockout mouse models.Frontiers in cell and developmental biology · 2023Review
- Increased Expression of SRSF1 Predicts Poor Prognosis in Multiple Myeloma.Journal of oncology · 2023Article
- Deciphering the role of RNA structure in translation efficiency.BMC bioinformatics · 2022Article
- Alternative RNA splicing modulates ribosomal composition and determines the spatial phenotype of glioblastoma cells.Nature cell biology · 2022Article
- A Rapid Translational Immune Response Program in CD8 Memory T Lymphocytes.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer.Cancers · 2022Article
- Cell autonomous and non-autonomous consequences of deviations in translation machinery on organism growth and the connecting signalling pathways.Open biology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
The oncogenic c-MYC (MYC) transcription factor has broad effects on gene expression and cell behavior. We show that MYC alters the efficiency and quality of mRNA translation into functional proteins. Specifically, MYC drives the translation of most protein components of the electron transport chain in lymphoma cells, and many of these effects are independent from proliferation. Specific interactions of MYC-sensitive RNA-binding proteins (e.g., SRSF1/RBM42) with 5'UTR sequence motifs mediate many of these changes. Moreover, we observe a striking shift in translation initiation site usage. For example, in low-MYC conditions, lymphoma cells initiate translation of the CD19 mRNA from a site in exon 5. This results in the truncation of all extracellular CD19 domains and facilitates escape from CD19-directed CAR-T cell therapy. Together, our findings reveal MYC effects on the translation of key metabolic enzymes and immune receptors in lymphoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.